Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr:69-70:67-80.
doi: 10.1016/j.addr.2013.12.002. Epub 2013 Dec 17.

Tissue-engineered kidney disease models

Teresa M Desrochers  1 , Erica Palma  1 , David L Kaplan  2
Affiliations
Review

Tissue-engineered kidney disease models

Teresa M Desrochers et al. Adv Drug Deliv Rev. 2014 Apr.

Abstract

Renal disease represents a major health problem that often results in end-stage renal failure necessitating dialysis and eventually transplantation. Historically these diseases have been studied with patient observation and screening, animal models, and two-dimensional cell culture. In this review, we focus on recent advances in tissue engineered kidney disease models that have the capacity to compensate for the limitations of traditional modalities. The cells and materials utilized to develop these models are discussed and tissue engineered models of polycystic kidney disease, drug-induced nephrotoxicity, and the glomerulus are examined in detail. The application of these models has the potential to direct future disease treatments and preclinical drug development.

Keywords: 3D tissues; Acute kidney injury; Chronic kidney disease; Drug-induced nephrotoxicity; Glomerulus; Microfluidics; Polycystic kidney disease; Renal; Renal cell carcinoma; Renal fibrosis.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Schematic representation of the different cellular components of the nephron and their roles in vivo.
Fig. 2
Fig. 2
Schematic representation of the process of glomerular tissue engineering.
See this image and copyright information in PMC

References

    1. Gibbons MC, Foley MA, Cardinal KO. Thinking inside the box: keeping tissue-engineered constructs in vitro for use as preclinical models. Tissue Eng Part B Rev. 2013;19:14–30. - PubMed
    1. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van DK, Smith P, Berger B, Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000;32:56–67. - PubMed
    1. Knight A. Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Rev Recent Clin. Trials. 2008;3:89–96. - PubMed
    1. Hartung T. Three Rs potential in the development and quality control of pharmaceuticals. ALTEX. 2001;18(Suppl 1):3–13. - PubMed
    1. Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Roi AJ, Prieto P, Sabbioni E, Worth A, Zuang V. ECVAM’s response to the changing political environment for alternatives: consequences of the European Union chemicals and cosmetics policies. Altern. Lab Anim. 2003;31:473–481. - PubMed

Publication types

MeSH terms